Sri Kosuri, Octant CEO
Synthetic biology biotech nets three-hit combo in new financing, Bristol Myers deal and first CSO
A Bay Area biotech announced three new developments that have been in the works in recent months, hoping that all have a strong chance at …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
